| GUIDELINES |
|
| Year : 2008 | Volume
: 3
| Issue : 6 | Page : 100-103 |
|
|
Treatment for small-cell lung cancer
Ahmed Saadeen1, Abdul-Rahman Jazieh2
1 Riyadh Military Hospital, Riyadh, Saudi Arabia
2 King Abdulaziz Medical City, Riyadh, Saudi Arabia
Correspondence Address:
Ahmed Saadeen
Department of Oncology (Bldg 1), Riyadh Military Hospital, P.O. Box 7897, Riyadh 11159
Saudi Arabia
 Source of Support: None, Conflict of Interest: None  | Check |
|
|
|
Small-cell lung cancer (SCLC) accounts for 13-20% of all lung cancers. Stongly associated with smoking and initially responsive to treatment, it results in death within 2-4 months without treatment. Limited-stage disease is treated with curative intent with chemotherapy and radiation therapy, with approximately 20% of patients achieving a cure. Extensive-stage disease is primarily treated with chemotherapy and has a high initial response rate of 60-70% but the median survival is only 10 months. All patients achieving a complete remission should be offered prophylactic cranial irradiation. Relapsed or refractory SCLC has a uniformly poor prognosis. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
Next article
